C3 Protein (Complement Component 3) is a central hub of the complement system and plays a critical role in innate immunity and neuroinflammation. It is one of the most abundant proteins in the complement system and serves as a convergence point for all three complement activation pathways. In the central nervous system, C3 is produced by neurons, astrocytes, microglia, and oligodendrocytes, making it a key mediator of neuroinflammatory processes in neurodegenerative diseases.
| C3 Protein (Complement Component 3) | |
|---|---|
| Protein Name | Complement Component 3 (C3) |
| Gene Symbol | C3 |
| UniProt ID | P01024 |
| Molecular Weight | ~185 kDa (alpha chain: ~110 kDa, beta chain: ~70 kDa) |
| Protein Family | [Complement System](/mechanisms/complement-system), Alpha-2-macroglobulin family |
| Subcellular Localization | Secreted, plasma, cytoplasm |
| Brain Expression | [Neurons](/entities/neurons), [astrocytes](/entities/astrocytes), microglia, oligodendrocytes |
| Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), [Multiple Sclerosis](/diseases/multiple-sclerosis) |
Complement Component 3 (C3) is the central molecule of the complement system, a key component of innate immunity. The complement system consists of over 50 proteins that work together to opsonize pathogens, recruit immune cells, and lyse foreign cells. C3 is the most abundant complement protein in plasma and serves as the convergence point for all three complement activation pathways: the classical pathway, the lectin pathway, and the alternative pathway [1].
In the brain, C3 plays a dual role. Under normal conditions, it contributes to synaptic pruning during development, a process by which excess synapses are eliminated to refine neural circuits [2]. However, dysregulated complement activation is implicated in the pathogenesis of multiple neurodegenerative diseases, where excessive complement activation contributes to neuroinflammation, synaptic loss, and progressive neuronal damage [3].
C3 is a large glycoprotein composed of an alpha chain (~110 kDa) and a beta chain (~70 kDa) linked by disulfide bonds:
| Feature | Description |
|---|---|
| Thioester bond | Reactive cysteine-methionine ester that covalently bonds to hydroxyl or amine groups on pathogen surfaces |
| Protease cleavage sites | Multiple sites for factor I-mediated cleavage and downstream complement activation |
| Conformational changes | Dramatic structural rearrangements upon activation expose functional domains |
C3 serves as the central hub for all three complement activation pathways:
Initiated by antigen-antibody complexes (C1q binding to IgG/IgM), leading to C1r/C1s activation, which then cleaves C4 and C2 to form the C3 convertase (C4b2a).
Activated by mannose-binding lectin (MBL) or ficolins binding to carbohydrate patterns on pathogens, also leading to C4b2a formation.
Spontaneous C3 tick-over produces C3(H2O), which then binds Factor B. Factor D cleaves Factor B to form the C3 convertase (C3bBb), which can amplify complement activation on surfaces that lack complement regulators.
| Function | Description | Mechanism |
|---|---|---|
| Opsonization | Marks pathogens for phagocytosis | C3b covalently attaches to pathogen surfaces |
| Inflammation | Recruits immune cells | C3a anaphylatoxin releases histamine from mast cells |
| Cell lysis | Direct pathogen killing | C5b-9 membrane attack complex formation |
| Immune clearance | Removes immune complexes | C3b/d receptors on erythrocytes and macrophages |
| Synaptic pruning | Developmental refinement | Complement-mediated synapse elimination |
In the central nervous system, complement proteins serve specialized functions:
C3 plays a significant role in Alzheimer's disease pathogenesis through multiple mechanisms:
In Parkinson's disease, C3 contributes to dopaminergic neuron degeneration:
C3 plays a role in motor neuron degeneration:
Complement is central to demyelination in MS:
The complement cascade in the brain differs from systemic complement:
C3a and C3b trigger distinct signaling cascades:
Complement interacts with other neuroinflammatory pathways:
Complement inhibitors represent a promising therapeutic approach for neurodegenerative diseases:
| Drug/Agent | Target | Status | Company/Indication |
|---|---|---|---|
| Eculizumab | C5 | Approved (PNH, aHUS) | Alexion - Exploring CNS indications |
| Ravulizumab | C5 | Approved (PNH, aHUS) | Alexion - Long-acting eculizumab |
| Pegcetacoplan | C3 | Approved (PNH) | Apellis - Geographic atrophy |
| AMY-101 | C3 | Phase 2 | Amyndas - Periodontitis, MS |
| Avacopan | C5aR | Approved (ANCA vasculitis) | ChemoCentryx - Exploring CNS |
| Agent | Mechanism | Research Stage |
|---|---|---|
| C3aR antagonists | Block C3a signaling | PD models |
| C3 Convertase inhibitors | Prevent C3b generation | Animal models |
| CR3 agonists | Enhance phagocytosis | Preclinical |
| C1q inhibitors | Prevent upstream activation | AD models |
Key experimental models for studying C3 in neurodegeneration:
C3 and its cleavage products serve as potential biomarkers: